|DB00196||Fluconazole||For the treatment of fungal infections.|
|DB00619||Imatinib||For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).|
|DB00673||Aprepitant||For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).|
|DB00705||Delavirdine||For the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted|
|DB00834||Mifepristone||For the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.|
|DB01319||Fosamprenavir||Indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission. The use of fosamprenavir is pending revision due to a potential association between the drug and myocardial infarction and dyslipidemia in HIV infected adults.|
|DB00199||Erythromycin||For use in the treatment of infections caused by susceptible strains of microorganisms in the following diseases: respiratory tract infections (upper and lower) of mild to moderate degree, pertussis (whooping cough), as adjunct to antitoxin in infections due to Corynebacterium diphtheriae, in the treatment of infections due to Corynebacterium minutissimum, intestinal amebiasis caused by Entamoeba histolytica, acute pelvic inflammatory disease caused by Neisseria gonorrhoeae, skin and soft tissue infections of mild to moderate severity caused by Streptococcus pyogenes and Staphylococcus aureus, primary syphilis caused by Treponema pallidum, infections caused by Chlamydia trachomatis, nongonococcal urethritis caused by Ureaplasma urealyticum, and Legionnaires' disease caused by Legionella pneumophila.|
|DB00176||Fluvoxamine||Indicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) [FDA Label]. Has also been used in the management of bulimia nervosa [A250].|
|DB00091||Cyclosporine||For treatment of transplant (kidney, liver, and heart) rejection, rheumatoid arthritis, severe psoriasis. |
|DB00661||Verapamil||For the treatment of hypertension, angina, and cluster headache prophylaxis.|
|DB04855||Dronedarone||Management of paroxysmal or persistent atrial fibrillation via restoration of normal sinus rhythm. |
|DB08865||Crizotinib||Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test. |
|DB08933||Luliconazole||Luliconazole is indicated in adults aged 18 years and older for the topical treatment of fungal infections caused by Trichophyton rubrum and Epidermophyton floccosum, specifically tinea pedis, cruris, and corporis.
|DB06636||Isavuconazonium||Indicated in the treatment of invasive aspergillosis and invasive mucormycosis.|
|DB09048||Netupitant||Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy.|
|DB11633||Isavuconazole||- Indicated for patients 18 years of age and older for the treatment of invasive aspergillosis [FDA Label].
- Indicated for patients 18 years of age and older for the treatment of invasive mucormycosis [FDA Label], including patients where treatment amphotericin B is inappropriate [L1482].|
|DB01118||Amiodarone||Intravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia.|
|DB01110||Miconazole||For topical application in the treatment of tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor.|
|DB00343||Diltiazem||For the treatment of Hypertension|
|DB00701||Amprenavir||For the treatment of HIV-1 infection in combination with other antiretroviral agents.|
|DB00622||Nicardipine||Used for the management of patients with chronic stable angina and for the treatment of hypertension.|
|DB00951||Isoniazid||For the treatment of all forms of tuberculosis in which organisms are susceptible.|
|DB01406||Danazol||For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.|
|DB00227||Lovastatin||For management as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia. For primary prevention of coronary heart disease and to slow progression of coronary atherosclerosis in patients with coronary heart disease. |
|DB00246||Ziprasidone||For the treatment of schizophrenia and related psychotic disorders.|
|DB00734||Risperidone||Risperidone belongs to the class of medications known as second generation atypical antipsychotics [A1114, A1115, L1213]. It is widely used in the treatment of schizophrenia and mood disorders, including bipolar disorder and depression with pyschosis [A1115, A1116, L1212, L1213].|
|DB09074||Olaparib||* Indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
* Indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
* Indicated for the treatment of patients with germline breast cancer susceptibility gene (BRCA) mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, who have been previously treated with chemotherapy.|
|DB06700||Desvenlafaxine||Desvenlafaxine is indicated for the treatment of major depressive disorder in adults.|
|DB00715||Paroxetine||Labeled indications include: major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD). Unlabeled indications include: eating disorders, impulse control disorders, vasomotor symptoms of menopause, obsessive-compulsive disorder (OCD) in children, and mild dementia-associated agitation in nonpsychotic individuals. Brisdelle, which consists of paroxetine mesylate is indicated for the treatment of moderate to severe vasomotor symptoms (like hot flashes) associated with menopause. |
|DB01104||Sertraline||For the management of major depressive disorder (MDD), posttraumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD) with or without agoraphobia, premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD) [FDA Label].
It may be used for premature ejaculation and vascular headaches as off-label indications. |
|DB04832||Zimelidine||For the treatment of depression.|
|DB04896||Milnacipran||Milnacipran is used to treat moderate to severe clinical depression but this indication is not yet FDA-approved in the USA. Milnacipran is labelled for the treatment of fibromyalgia pain. |
|DB00285||Venlafaxine||For the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (social phobia), panic disorder with or without agoraphobia, vasomotor symptoms in women with breast cancer and in postmenopausal women, and neuropathic pain.|
|DB02703||Fusidic Acid||For the treatment of bacterial infections.|
|DB09227||Barnidipine||Indicated for the treatment of mild to moderate essential hypertension and management of chronic stable angina.|
|DB09231||Benidipine||Benidipine is a potent and long-lasting drug indicated for the treatment of cardiovascular diseases such as hypertension, renoparenchymal hypertension and angina pectoris.[A31950]|
|DB00270||Isradipine||For the management of mild to moderate essential hypertension. It may be used alone or concurrently with thiazide-type diuretics.|
|DB00502||Haloperidol||For the treatment of schizophrenia [L2016]
For the treatment of acute psychosis in acutely agitated schizophrenic patients with moderately severe to very severe symptoms [L2016]
For the treatment of severe behavioral or psychological symptoms of dementia [L2016]
For the treatment of delirium in the pediatric intensive care unit [L2016]
For the treatment of agitation or delirium [L2016]
For agitation† or delirium in adult patients with no underlying psychiatric illness [L2016]
For use as a second-line agent for rescue treatment of chemotherapy-induced nausea/vomiting [L2016]
For the treatment of irritability associated with autistic disorder [L2016]
For the treatment of tics and vocal utterances associated with Tourette's syndrome [L2016]
For the treatment of severe behavioral problems associated with oppositional defiant disorder or other disruptive behavioral disorders, or for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients who show excessive motor activity with accompanying conduct disorders [L2016]|
|DB08882||Linagliptin||Linagliptin is used for the management of type 2 diabetes mellitus. |
|DB14019||Fosnetupitant||Indicated in combination palonosetron (as the drug Akynzeo) and dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy [FDA label].
The following are indications listed on the EMA label [F29]:
Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy [F29].
Prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy [F29].|
|DB06290||Simeprevir||Indicated for the treatment of adults with chronic hepatitis C virus (HCV) infection: typically in combination with sofosbuvir in patients with HCV genotype 1 without cirrhosis or with compensated cirrhosis and in combination with peginterferon alfa (Peg-IFN-alfa) and ribavirin (RBV) in patients with HCV genotype 1 or 4 without cirrhosis or with compensated cirrhosis.
Resistance: Reduced susceptibility to simeprevir was most commonly associated with the viral NS3 Q80K polymorphism. Amino acid substitutions at NS3 positions S122, R155 and/or D168 are also shown to reduce susceptibility to simeprevir in genotype 1a/b patients.
|DB06712||Nilvadipine||For the management of vasospastic angina, chronic stable angina and hypertension.|
|DB01087||Primaquine||For the treatment of malaria.|
|DB00363||Clozapine||For use in patients with treatment-resistant schizophrenia.|
|DB01217||Anastrozole||For adjuvant treatment of hormone receptor positive breast cancer , as well as hormonal treatment of advanced breast cancer in post-menopausal women. Has also been used to treat pubertal gynecomastia and McCune-Albright syndrome; however, manufacturer states that efficacy for these indications have not been established.|
|DB01093||Dimethyl sulfoxide||For the symptomatic relief of patients with interstitial cystitis.|
|DB01007||Tioconazole||For the local treatment of vulvovaginal candidiasis (moniliasis).|